|
Bay Area Tumor Institute CCOP
|
5U10CA045461-20
|
$521,201
|
$5,212
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
Localization and Function of iNKT Cells in Neuroblastoma
|
7R01CA116548-05
|
$229,963
|
$229,963
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Safety/Efficacy of Liposomal Reversan, a novel MRP1 modulator for Cancer Therapy
|
1R41CA137977-01
|
$104,608
|
$34,521
|
Sen, Arindam
|
BUFFALO BIOLABS, LLC
|
|
Plasminogen activator inhibitor-1 in tumor progression and metastasis
|
5R01CA129377-02
|
$239,794
|
$239,794
|
DeClerck, Yves
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Biology and Therapy of High Risk Neuroblastoma
|
5P01CA081403-10
|
$1,950,665
|
$1,950,665
|
SEEGER, ROBERT
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Clinical Correlative Studies of Neuroblastoma
|
5R01CA060104-16
|
$421,986
|
$421,986
|
SEEGER, ROBERT
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
Virotherapy for Neuroblastoma Stem Cells
|
5R21CA133663-02
|
$202,500
|
$202,500
|
CRIPE, TIMOTHY
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
|
Targeting Oncolytic HSV to Neuroblastoma & Malig. Peripheral Nerve Sheath Tumors
|
5F31CA132613-02
|
$32,933
|
$16,467
|
Maldonado, Arturo
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
|
Discovery of Chromosome Arm 11q Tumor Suppressor Genes in Neuroblastoma
|
5K08CA123100-04
|
$139,320
|
$139,320
|
ATTIYEH, EDWARD
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
Molecular Genetic Analysis of Human Neuroblastoma
|
2R01CA039771-21A2
|
$388,815
|
$388,815
|
BRODEUR, GARRETT
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
Trk Expression and Inhibition in Human Neuroblastomas
|
5R01CA094194-07
|
$378,136
|
$378,136
|
BRODEUR, GARRETT
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
Translational Genomics of MicroRNAs in Neuroblastoma
|
1K08CA136979-01
|
$154,347
|
$154,347
|
COLE, KRISTINA
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
Optimizing Pro-Apoptotic Therapeutics With Kinase Inhibition in Neuroblastoma
|
5K08CA128925-02
|
$34,830
|
$34,830
|
Goldsmith, Kelly
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
The Genetic Basis of Neuroblastoma Tumorigenesis
|
5R01CA124709-02
|
$666,482
|
$666,482
|
MARIS, JOHN
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
Targeting Oncogenic ALK Signaling in Neuroblastoma
|
1R01CA140198-01
|
$343,973
|
$343,973
|
Mosse, YAEL
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
GENOMICS OF HUMAN NEUROBLASTOMA
|
5K08CA111733-05
|
$124,800
|
$124,800
|
Mosse, YAEL
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
Delaware/Christiana Care CCOP
|
5U10CA045418-23
|
$1,282,700
|
$12,827
|
Grubbs, Stephen
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
Cancer Center Support Grant
|
3P30CA033572-26S1
|
$94,753
|
$2,843
|
FIGLIN, ROBERT
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-26S2
|
$107,415
|
$3,222
|
FIGLIN, ROBERT
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-26S3
|
$100,000
|
$3,000
|
FIGLIN, ROBERT
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
5P30CA033572-26
|
$2,342,475
|
$70,274
|
FIGLIN, ROBERT
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Clinical Trials Reporting Program (CTRP) Early Adopters
|
3P30CA013696-36S1
|
$99,928
|
$1,999
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-36
|
$3,999,822
|
$79,996
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
VEGF blockade and alternative angiogenic pathways in neuroblastoma
|
5R01CA124644-02
|
$334,075
|
$334,075
|
YAMASHIRO, DARRELL
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
"Oncorequisite" Genes in MYC-mediated Transformation
|
1K99CA134743-01A1
|
$140,940
|
$28,188
|
FENG, HUI
|
DANA-FARBER CANCER INSTITUTE
|
|
Duluth Community Clinical Oncology Program
|
5U10CA035269-26
|
$747,046
|
$7,470
|
Nikcevich, Daniel
|
DULUTH CLINIC, LTD.
|
|
Optimizing Pro-Apoptotic Therapeutics With Kinase Inhibition in Neuroblastoma
|
7K08CA128925-03
|
$104,490
|
$104,490
|
Goldsmith, Kelly
|
EMORY UNIVERSITY
|
|
MDM2 regulates XIAP gene expression in cancer treatment
|
5R01CA123490-02
|
$257,300
|
$64,325
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
EORTC DATA CENTER
|
5U10CA011488-39
|
$809,323
|
$8,093
|
Sylvester, Richard
|
EUROPEAN ORG/RES/TREATMENT/CANCER
|
|
Community Clinical Oncology Program: FL Pediatric CCOP
|
5U10CA035157-26
|
$382,772
|
$11,483
|
TALBERT, JAMES
|
FLORIDA ASSN OF PEDIATRIC TUMOR PROG
|
|
Pediaric Oncology Research Training Program
|
5T32CA009351-31
|
$223,195
|
$11,160
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Neuropeptide Y in neuroblastoma: growth, angiogenesis and future therapeutics.
|
5R01CA123211-04
|
$267,492
|
$267,492
|
KITLINSKA, JOANNA
|
GEORGETOWN UNIVERSITY
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA051008-16S8
|
$2,988,363
|
$29,884
|
WEINER, LOUIS
|
GEORGETOWN UNIVERSITY
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA051008-16S9
|
$110,862
|
$1,109
|
WEINER, LOUIS
|
GEORGETOWN UNIVERSITY
|
|
Iowa Oncology Research Association
|
5U10CA035101-24
|
$865,544
|
$8,655
|
Behrens, Robert
|
IOWA ONCOLOGY RESEARCH ASSOCIATION
|
|
LSUHSC Minority-Based Community Clinical Oncology Program
|
2U10CA063845-11
|
$710,000
|
$7,100
|
VEITH, ROBERT
|
LOUISIANA STATE UNIV HSC NEW ORLEANS
|
|
mTOR Signaling in Tumor Cell Motility
|
5R01CA115414-04
|
$201,997
|
$40,399
|
Huang, Shile
|
LOUISIANA STATE UNIV HSC SHREVEPORT
|
|
Marshfield Community Clinical Oncology Program
|
5U10CA035412-26
|
$926,378
|
$9,264
|
Weiss, Matthias
|
MARSHFIELD CLINIC RESEARCH FOUNDATION
|
|
The oncogenic basis of Bmi-1 in neuroblastoma development
|
5R01CA124982-03
|
$279,300
|
$279,300
|
DING, HAN-FEI
|
MEDICAL COLLEGE OF GEORGIA (MCG)
|
|
MCG Minority-Based Community Clinical Oncology Program
|
3U10CA107586-06S1
|
$100,000
|
$1,000
|
Jillella, Anand
|
MEDICAL COLLEGE OF GEORGIA (MCG)
|
|
MCG Minority-Based Community Clinical Oncology Program
|
5U10CA107586-06
|
$550,477
|
$5,505
|
Jillella, Anand
|
MEDICAL COLLEGE OF GEORGIA (MCG)
|
|
Optimizing Immunotherapy for Neuroblastoma after BMT
|
2R01CA100030-06
|
$304,318
|
$304,318
|
JOHNSON, BRYON
|
MEDICAL COLLEGE OF WISCONSIN
|
|
Nanodosing: A path to higher sensitivity and lower toxicity pharmaceuticals
|
5R44CA130394-03
|
$496,373
|
$248,187
|
Kronauge, James
|
MOLECULAR INSIGHT PHARMACEUTICALS, INC.
|
|
Children's Oncology Group Statistics and Data Center Grant
|
5U10CA098413-07
|
$5,725,544
|
$286,277
|
ANDERSON, JAMES
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Community Clinical Oncology program Research Base
|
5U10CA095861-08
|
$2,126,089
|
$106,304
|
POLLOCK, BRAD
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Children's Oncology Group Chair's Grant
|
3U10CA098543-07S3
|
$749,797
|
$37,490
|
REAMAN, GREGORY
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Children's Oncology Group Chair's Grant
|
5U10CA098543-07
|
$27,646,062
|
$1,382,303
|
REAMAN, GREGORY
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Support for Human Specimen Banking in NCI-Supported Cancer Clinical Trials
|
5U24CA114766-05
|
$1,195,618
|
$239,124
|
REAMAN, GREGORY
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Clinical Pharmacology of Anticancer Drugs
|
ZIA BC 011080
|
$923,641
|
$92,364
|
Balis, Frank
|
CCR (NCI)
|
|
Anticancer Drug Development for Childhood Cancers
|
ZIA SC 006880
|
$831,277
|
$332,511
|
Balis, Frank
|
CCR (NCI)
|
Total relevant funding to Neuroblastoma for this search: $19,489,203
|